Research output per year
Research output per year
Personal profile
Biography
Andy Redfern is Associate Professor of Medical Oncology at the University of Western Australia, Associate Director for Clinical Strategy at Harry Perkins Institute of Medical Research, Consultant Medical Oncologist at the Fiona Stanley Hospital, Perth, and Medical Director of Linear Clinical Research specialising in early phase human trials.
Beyond a clinical practice treating breast and urological cancers, Andy is principal investigator for a range of clinical trials across all phases and has a portfolio of translational research initiatives. His research interests centre around growth signalling and mechanisms of chemotherapy and hormone therapy resistance in cancer, differentiation and EMT in cancer progression, tumour-stroma interactions and Indigenous cancer biology.
Andy is also chairman and lead clinician of the State Breast Cancer Collaborative and is on scientific advisory boards for the Cancer Council of Western Australia and the Australasian Breast Cancer Trials Group.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research expertise keywords
- cancer growth signalling
- chemotherapy resistance
- hormone therapy resistance
- cancer progression
- tumour-stroma interactions
Fingerprint
Dive into the research topics where Andrew Redfern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Nguyen, A., Francis, R. J. & Redfern, A. D., May 2024, In: The Lancet Oncology. 25, 5, p. 563-571 9 p.Research output: Contribution to journal › Article › peer-review
12 Citations (Scopus) -
Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence
Martin, H. & Redfern, A., Jan 2024, In: Cancer Medicine. 13, 1, e6846.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparing Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in staging for nodal and distant metastasis in urothelial/bladder cancer
Al-Zubaidi, M., Ong, K., Viswambaram, P., Bangash, H., Boardman, G., McCombie, S. P., Oey, O., Swarbrick, N., Redfern, A., Ong, J., Gauci, R., Low, R. & Hayne, D., Apr 2024, In: BJUI Compass. 5, 4, p. 473-479 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Editorial: Reviews and advances in the molecular mechanisms of breast cancer
Redfern, A., Agarwal, V. & Alahari, S., 2024, In: Frontiers in Cell and Developmental Biology. 12, 1380475.Research output: Contribution to journal › Editorial › peer-review
Open Access -
Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study
Kim, J. S., Taaffe, D. R., Galvão, D. A., Clay, T. D., Redfern, A. D., Gray, E. S. & Newton, R. U., Dec 2024, In: BMC Cancer. 24, 1, 784.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
Additional file 7 of Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling
Chi, L. H. (Creator), Redfern, A. (Creator), Roslan, S. (Creator), Street, I. P. (Creator), Burrows, A. D. (Creator) & Anderson, R. L. (Creator), Figshare, 15 Aug 2024
DOI: 10.6084/m9.figshare.26714428.v1, https://springernature.figshare.com/articles/dataset/Additional_file_7_of_Loss_of_tumor-derived_SMAD4_enhances_primary_tumor_growth_but_not_metastasis_following_BMP4_signalling/26714428/1
Dataset
-
Additional file 9 of Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling
Chi, L. H. (Creator), Redfern, A. (Creator), Roslan, S. (Creator), Street, I. P. (Creator), Burrows, A. D. (Creator) & Anderson, R. L. (Creator), Figshare, 15 Aug 2024
DOI: 10.6084/m9.figshare.26714434.v1, https://springernature.figshare.com/articles/dataset/Additional_file_9_of_Loss_of_tumor-derived_SMAD4_enhances_primary_tumor_growth_but_not_metastasis_following_BMP4_signalling/26714434/1
Dataset
-
Additional file 5 of Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
Takano, E. A. (Creator), Younes, M. M. (Creator), Meehan, K. (Creator), Spalding, L. (Creator), Yan, M. (Creator), Allan, P. (Creator), Fox, S. B. (Creator), Redfern, A. (Creator), Clouston, D. (Creator), Giles, G. G. (Creator), Christie, E. L. (Creator), Anderson, R. L. (Creator), Zethoven, M. (Creator), Phillips, K. (Creator), Gorringe, K. (Creator) & Britt, K. L. (Creator), Figshare, 19 May 2023
DOI: 10.6084/m9.figshare.22978079.v1, https://springernature.figshare.com/articles/dataset/Additional_file_5_of_Estrogen_receptor_beta_expression_in_triple_negative_breast_cancers_is_not_associated_with_recurrence_or_survival/22978079/1
Dataset
-
Additional file 5 of Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
Takano, E. A. (Creator), Younes, M. M. (Creator), Meehan, K. (Creator), Spalding, L. (Creator), Yan, M. (Creator), Allan, P. (Creator), Fox, S. B. (Creator), Redfern, A. (Creator), Clouston, D. (Creator), Giles, G. G. (Creator), Christie, E. L. (Creator), Anderson, R. L. (Creator), Zethoven, M. (Creator), Phillips, K. (Creator), Gorringe, K. (Creator) & Britt, K. L. (Creator), Figshare, 19 May 2023
DOI: 10.6084/m9.figshare.22978079, https://springernature.figshare.com/articles/dataset/Additional_file_5_of_Estrogen_receptor_beta_expression_in_triple_negative_breast_cancers_is_not_associated_with_recurrence_or_survival/22978079
Dataset
-
Targeting an alternate nuclear receptor to treat aggressive breast cancers.
Woo, A., Leedman, P., Blancafort, P., Wang, E., Winteringham, L., Redfern, A. & Artzi, N.
1/07/24 → 30/12/25
Project: Research
-
Therapeutic exploitation of Rab12, a novel tumour and metastasis suppressor in breast cancer
Wang, E., Blancafort, P., Redfern, A., Winteringham, L., Woo, A. & Khinsar, K. H.
1/01/24 → 30/06/25
Project: Research
-
TARGETING A NEW SUBTYPE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Blancafort, P., Redfern, A., Golden, E., Johnstone, L., Pavlos, N. & Sharma, A.
National Breast Cancer Foundation
31/05/22 → 31/05/26
Project: Research
-
MRFF RCRDUN - Addressing the poor outcomes of young women with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer
Redfern, A., Loi, S., Francis, P., Fox, S. & Wilcken, N.
Medical Research Future Fund MRFF
1/01/22 → 31/12/26
Project: Research